How much does it cost to develop a new drug?

Money for pharmaceutical drugs

The popular view of drug development is that it is fantastically expensive undertaking.  The most recent cost estimate (according to research published by the Tufts Center for the Study of Drug Development) is a whopping $1.3 billion.

Some would say that such a high cost is advantageous to the pharma industry since it creates a powerful argument for premium pricing and patent term extension.

But is the number true?

A recent report in the London School of Economics journal BioSocieties by Donald Light (University of Medicine & Dentistry of New Jersey/Stanford University) and Rebecca Warburton (University of Victoria) casts doubt on the hefty price tag.

In an interview with the Burrill Report (listen here), the authors cited the following problems with way the pharma development costs are calculated:

• Incomplete sampling of pharma companies
• Incomplete sampling of drugs for cost estimation
• Focus on new chemical entities only (only 22% of all drug approvals)
• Use of the mean cost instead of the median cost
• Use of an unrealistically high cost of capital (11%)
• Failure to deduct tax credit from the total cost (R&D is an expense)
• Inclusion of discovery costs (a large proportion of which were underwritten by public funds for academic research)

So what is the true cost?  The authors believe the actual cost of developing a new drug to approval is $59 million (or less) plus discovery cost.  Indeed, audited numbers for all trials reported to the IRS by pharmaceutical companies in the late 1990s put the figure even lower at $22.5 million (download the PDF report: “Evidence regarding research and development investments in innovative and non-innovative medicines”).

So who’s telling the truth?  One way to conclusively put the issue to rest would be for the pharma companies (who strongly dispute the authors’ findings) to disclose their audited R&D expenses for all drugs approved in the past five years.

Expect this issue to grow and grow as national health-care budgets come under increasing pressure.

Related Blogs

 

Can open innovation close the pharma productivity gap?
Analysis of research and development (R&D) expenditures compared to the number of new molecular entities approved by the Food and Drug Administration (FDA) each year indicates that there is defi

Ontario: Breaking through to the future of medicine
Ontario’s leading biomedical innovators are working with global leaders on the problems of infectious disease, improved drugs and health care. In December, the MaRS Future of Medicine™ 2010 Annua

Hit the road, JAK
YM BioSciences Inc., an oncology company based in the GTA, announced exciting clinical data at the recent America Society of Hematology (ASH) meeting. The study was in myelofibrosis – a severe

Generic drugs are cheaper?
We’ve all heard multinational pharmaceutical companies claim that the cost of developing a single new drug is over $1.0 billion. Even though that cost includes all failed development efforts,Â

The future of medicine's so bright
Imagine a world where… drugs work reliably no one ever gets sick from their prescriptions harmful properties are designed out of all new drugs critically-ill patients entering the ICU expect a po

InDanio secures funding
The Ontario Genomics Institute announced today that it has awarded MaRS client InDanio BioScience $100,000 of development funding under its Pre-Commercialization Business Development Fund (see press

Tags: drug development, John McCulloch, life sciences, research & development